1st Quarter - Report

WINNING STRATEGIES WASHINGTON for MEDA PHARMACEUTICALS

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA Risk Evaluation and Mitigation Strategies

LobbyistCovered position, as disclosed
ALEX DELPIZZO —
MICHAEL A MEROLA —
ROBERT ZUCKER New LD, Rep. Rothman; LA,Rep. Evans (IL);

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

FDA Risk Evaluation and Mitigation Strategies

LobbyistCovered position, as disclosed
ALEX DELPIZZO —
MICHAEL A MEROLA —
ROBERT ZUCKER New LD, Rep. Rothman; LA,Rep. Evans (IL)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.